David Fleischer
Concepts (473)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peanut Hypersensitivity | 58 | 2025 | 143 | 13.620 |
Why?
| | Food Hypersensitivity | 54 | 2026 | 165 | 10.630 |
Why?
| | Arachis | 45 | 2025 | 108 | 8.930 |
Why?
| | Allergens | 60 | 2026 | 390 | 8.340 |
Why?
| | Desensitization, Immunologic | 31 | 2025 | 91 | 5.930 |
Why?
| | Anaphylaxis | 14 | 2026 | 105 | 2.790 |
Why?
| | Infant Nutritional Physiological Phenomena | 12 | 2025 | 159 | 2.720 |
Why?
| | Immunoglobulin E | 34 | 2026 | 315 | 2.250 |
Why?
| | Diet | 18 | 2024 | 1271 | 2.180 |
Why?
| | Dermatitis, Atopic | 15 | 2025 | 319 | 1.900 |
Why?
| | Epinephrine | 7 | 2026 | 160 | 1.740 |
Why?
| | Milk Hypersensitivity | 8 | 2024 | 18 | 1.520 |
Why?
| | Transdermal Patch | 3 | 2020 | 14 | 1.370 |
Why?
| | Eosinophilic Esophagitis | 10 | 2021 | 333 | 1.360 |
Why?
| | Skin Tests | 20 | 2025 | 94 | 1.300 |
Why?
| | Egg Hypersensitivity | 12 | 2026 | 28 | 1.150 |
Why?
| | Plant Proteins | 4 | 2025 | 110 | 1.100 |
Why?
| | Esophagoscopy | 13 | 2022 | 223 | 1.070 |
Why?
| | Primary Prevention | 5 | 2022 | 222 | 1.040 |
Why?
| | Immunotherapy | 9 | 2024 | 669 | 1.040 |
Why?
| | Hypersensitivity | 4 | 2025 | 253 | 1.020 |
Why?
| | Antigens, Plant | 7 | 2025 | 55 | 1.000 |
Why?
| | Infant | 48 | 2026 | 10093 | 1.000 |
Why?
| | Anti-Allergic Agents | 6 | 2026 | 41 | 0.940 |
Why?
| | Humans | 175 | 2026 | 145625 | 0.910 |
Why?
| | Administration, Cutaneous | 11 | 2025 | 127 | 0.900 |
Why?
| | Gastrointestinal Diseases | 9 | 2019 | 220 | 0.890 |
Why?
| | Infant Formula | 4 | 2023 | 71 | 0.890 |
Why?
| | Child | 60 | 2025 | 22638 | 0.870 |
Why?
| | Child, Preschool | 40 | 2026 | 11888 | 0.840 |
Why?
| | Nut Hypersensitivity | 3 | 2010 | 5 | 0.810 |
Why?
| | Noncommunicable Diseases | 1 | 2023 | 21 | 0.780 |
Why?
| | Breast Feeding | 8 | 2023 | 447 | 0.770 |
Why?
| | Protein Hydrolysates | 3 | 2018 | 6 | 0.740 |
Why?
| | Eczema | 10 | 2022 | 66 | 0.720 |
Why?
| | Hypersensitivity, Immediate | 3 | 2023 | 41 | 0.700 |
Why?
| | Endoscopy, Gastrointestinal | 7 | 2022 | 236 | 0.680 |
Why?
| | Asthma | 9 | 2025 | 1800 | 0.670 |
Why?
| | Immune Tolerance | 9 | 2023 | 384 | 0.650 |
Why?
| | Esophageal Stenosis | 6 | 2015 | 60 | 0.590 |
Why?
| | Double-Blind Method | 15 | 2025 | 2064 | 0.580 |
Why?
| | Schools | 4 | 2021 | 436 | 0.580 |
Why?
| | Esophageal Neoplasms | 10 | 2022 | 351 | 0.580 |
Why?
| | Omalizumab | 4 | 2026 | 44 | 0.580 |
Why?
| | Female | 78 | 2026 | 79080 | 0.570 |
Why?
| | Nasal Sprays | 3 | 2026 | 6 | 0.490 |
Why?
| | Male | 66 | 2026 | 73014 | 0.490 |
Why?
| | Eosinophilia | 4 | 2013 | 224 | 0.470 |
Why?
| | Gastroenterology | 2 | 2015 | 185 | 0.460 |
Why?
| | Administration, Oral | 9 | 2022 | 867 | 0.450 |
Why?
| | Pneumonia, Viral | 4 | 2020 | 387 | 0.430 |
Why?
| | Coronavirus Infections | 4 | 2020 | 379 | 0.430 |
Why?
| | Lye | 1 | 2014 | 1 | 0.420 |
Why?
| | Caustics | 1 | 2014 | 6 | 0.420 |
Why?
| | Dilatation | 2 | 2014 | 73 | 0.410 |
Why?
| | Burns, Chemical | 1 | 2014 | 32 | 0.410 |
Why?
| | Adolescent | 26 | 2026 | 22451 | 0.410 |
Why?
| | Endosonography | 1 | 2015 | 160 | 0.410 |
Why?
| | Practice Guidelines as Topic | 9 | 2024 | 1581 | 0.390 |
Why?
| | Eggs | 3 | 2026 | 24 | 0.390 |
Why?
| | Feeding Behavior | 3 | 2019 | 691 | 0.380 |
Why?
| | Barrett Esophagus | 3 | 2022 | 172 | 0.380 |
Why?
| | Betacoronavirus | 3 | 2020 | 288 | 0.380 |
Why?
| | Food | 5 | 2024 | 149 | 0.370 |
Why?
| | Pandemics | 5 | 2020 | 1700 | 0.360 |
Why?
| | Environmental Exposure | 1 | 2017 | 578 | 0.360 |
Why?
| | Gastrointestinal Hemorrhage | 4 | 2007 | 133 | 0.340 |
Why?
| | Cattle | 4 | 2024 | 938 | 0.340 |
Why?
| | Allergy and Immunology | 3 | 2020 | 42 | 0.330 |
Why?
| | Infant Food | 2 | 2023 | 69 | 0.330 |
Why?
| | Esophagus | 8 | 2019 | 260 | 0.320 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2020 | 1754 | 0.310 |
Why?
| | Milk Proteins | 3 | 2024 | 33 | 0.310 |
Why?
| | Treatment Outcome | 13 | 2025 | 11744 | 0.300 |
Why?
| | Adenocarcinoma | 5 | 2022 | 927 | 0.300 |
Why?
| | Allergists | 3 | 2020 | 13 | 0.300 |
Why?
| | United States | 24 | 2024 | 16041 | 0.300 |
Why?
| | Endoscopy | 7 | 2018 | 316 | 0.300 |
Why?
| | Young Adult | 15 | 2026 | 14240 | 0.300 |
Why?
| | Biological Products | 2 | 2026 | 257 | 0.290 |
Why?
| | Risk | 5 | 2018 | 917 | 0.290 |
Why?
| | Virtual Reality | 2 | 2021 | 82 | 0.280 |
Why?
| | Cross-Over Studies | 3 | 2026 | 612 | 0.280 |
Why?
| | Administration, Sublingual | 4 | 2026 | 13 | 0.270 |
Why?
| | Adult | 28 | 2026 | 40821 | 0.270 |
Why?
| | Capsule Endoscopy | 1 | 2007 | 22 | 0.260 |
Why?
| | Consensus | 5 | 2021 | 465 | 0.260 |
Why?
| | Intestinal Diseases | 1 | 2007 | 43 | 0.260 |
Why?
| | Enterocolitis | 2 | 2020 | 18 | 0.250 |
Why?
| | Severity of Illness Index | 6 | 2019 | 2910 | 0.250 |
Why?
| | Colonoscopy | 4 | 2014 | 254 | 0.250 |
Why?
| | Adrenal Cortex Hormones | 3 | 2017 | 483 | 0.240 |
Why?
| | Brazil | 2 | 2023 | 178 | 0.240 |
Why?
| | Capsules | 2 | 2005 | 40 | 0.240 |
Why?
| | Time Factors | 7 | 2020 | 7079 | 0.230 |
Why?
| | Rhinitis, Allergic | 3 | 2022 | 41 | 0.230 |
Why?
| | Egg Proteins | 1 | 2026 | 14 | 0.230 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2026 | 25 | 0.230 |
Why?
| | Prodrugs | 1 | 2026 | 54 | 0.230 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 7 | 2019 | 25 | 0.230 |
Why?
| | Pregnancy | 9 | 2024 | 7217 | 0.210 |
Why?
| | Canada | 3 | 2020 | 430 | 0.210 |
Why?
| | Immunomodulation | 2 | 2018 | 98 | 0.210 |
Why?
| | Gastrointestinal Neoplasms | 3 | 2000 | 74 | 0.210 |
Why?
| | Age Factors | 7 | 2018 | 3321 | 0.210 |
Why?
| | Follow-Up Studies | 7 | 2020 | 5397 | 0.200 |
Why?
| | Healthy Volunteers | 2 | 2024 | 217 | 0.200 |
Why?
| | Diagnostic Imaging | 2 | 2006 | 340 | 0.190 |
Why?
| | Middle Aged | 24 | 2026 | 36359 | 0.190 |
Why?
| | Constipation | 1 | 2024 | 98 | 0.190 |
Why?
| | Eosinophils | 2 | 2018 | 319 | 0.190 |
Why?
| | Catheter Ablation | 2 | 2019 | 355 | 0.190 |
Why?
| | Laser Therapy | 5 | 1985 | 146 | 0.180 |
Why?
| | Intestinal Mucosa | 2 | 2015 | 666 | 0.180 |
Why?
| | Animals | 14 | 2026 | 38030 | 0.180 |
Why?
| | Food Analysis | 1 | 2022 | 22 | 0.180 |
Why?
| | Gastroesophageal Reflux | 2 | 2022 | 232 | 0.170 |
Why?
| | Point-of-Care Testing | 1 | 2022 | 36 | 0.170 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 2097 | 0.170 |
Why?
| | Milk | 3 | 2018 | 117 | 0.170 |
Why?
| | Child Day Care Centers | 1 | 2021 | 36 | 0.170 |
Why?
| | Dietary Exposure | 1 | 2020 | 9 | 0.160 |
Why?
| | Aptamers, Nucleotide | 1 | 2022 | 88 | 0.160 |
Why?
| | Restaurants | 1 | 2020 | 25 | 0.160 |
Why?
| | Diet Therapy | 2 | 2017 | 36 | 0.160 |
Why?
| | Infusions, Subcutaneous | 1 | 2020 | 23 | 0.160 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2020 | 116 | 0.150 |
Why?
| | Deglutition Disorders | 2 | 2019 | 159 | 0.150 |
Why?
| | Immunization | 3 | 2017 | 375 | 0.150 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1500 | 0.150 |
Why?
| | Inservice Training | 1 | 2020 | 114 | 0.150 |
Why?
| | Europe | 2 | 2022 | 420 | 0.150 |
Why?
| | Respiratory Tract Infections | 1 | 2024 | 399 | 0.150 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2024 | 662 | 0.150 |
Why?
| | Multiphasic Screening | 1 | 2018 | 1 | 0.140 |
Why?
| | Prevalence | 4 | 2024 | 2852 | 0.140 |
Why?
| | Confidence Intervals | 1 | 2019 | 328 | 0.140 |
Why?
| | Population Groups | 1 | 2018 | 55 | 0.140 |
Why?
| | Quality of Life | 6 | 2022 | 3187 | 0.140 |
Why?
| | Meta-Analysis as Topic | 2 | 2016 | 173 | 0.140 |
Why?
| | Blood Pressure | 1 | 2025 | 1761 | 0.130 |
Why?
| | United Kingdom | 4 | 2020 | 376 | 0.130 |
Why?
| | Food, Genetically Modified | 1 | 2017 | 2 | 0.130 |
Why?
| | Coal Tar | 1 | 2017 | 2 | 0.130 |
Why?
| | Skin Cream | 1 | 2017 | 11 | 0.130 |
Why?
| | Keratolytic Agents | 1 | 2017 | 4 | 0.130 |
Why?
| | Emollients | 1 | 2017 | 11 | 0.130 |
Why?
| | Monitoring, Physiologic | 2 | 1990 | 278 | 0.130 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2017 | 11 | 0.130 |
Why?
| | Plants, Genetically Modified | 1 | 2017 | 16 | 0.130 |
Why?
| | Baths | 1 | 2017 | 14 | 0.130 |
Why?
| | Histamine Antagonists | 1 | 2017 | 21 | 0.130 |
Why?
| | Crops, Agricultural | 1 | 2017 | 30 | 0.130 |
Why?
| | Clothing | 1 | 2017 | 23 | 0.130 |
Why?
| | School Health Services | 1 | 2020 | 217 | 0.130 |
Why?
| | Ambulatory Care Facilities | 1 | 2020 | 267 | 0.130 |
Why?
| | Health Promotion | 1 | 2024 | 786 | 0.130 |
Why?
| | Calcineurin Inhibitors | 1 | 2017 | 67 | 0.130 |
Why?
| | Mothers | 1 | 2023 | 771 | 0.120 |
Why?
| | Telemedicine | 3 | 2020 | 956 | 0.120 |
Why?
| | Risk Assessment | 4 | 2019 | 3678 | 0.120 |
Why?
| | Basophils | 2 | 2015 | 52 | 0.120 |
Why?
| | Nutritionists | 1 | 2016 | 24 | 0.120 |
Why?
| | Eating | 1 | 2019 | 386 | 0.120 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 130 | 0.120 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 102 | 0.120 |
Why?
| | Prognosis | 2 | 2020 | 4331 | 0.120 |
Why?
| | Kidney Transplantation | 1 | 2022 | 702 | 0.120 |
Why?
| | Bottle Feeding | 1 | 2016 | 19 | 0.120 |
Why?
| | Indonesia | 1 | 2015 | 23 | 0.110 |
Why?
| | Surveys and Questionnaires | 7 | 2024 | 6050 | 0.110 |
Why?
| | Health Care Reform | 2 | 1994 | 109 | 0.110 |
Why?
| | Infant, Newborn | 6 | 2024 | 6449 | 0.110 |
Why?
| | Nutritional Requirements | 1 | 2016 | 78 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2022 | 1130 | 0.110 |
Why?
| | Decision Support Techniques | 1 | 2020 | 473 | 0.110 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2015 | 34 | 0.110 |
Why?
| | Sublingual Immunotherapy | 1 | 2015 | 4 | 0.110 |
Why?
| | Probiotics | 1 | 2015 | 61 | 0.110 |
Why?
| | Fluticasone | 1 | 2015 | 53 | 0.110 |
Why?
| | Carcinoma in Situ | 1 | 2015 | 45 | 0.110 |
Why?
| | Injections, Intramuscular | 2 | 2026 | 140 | 0.110 |
Why?
| | History, 21st Century | 1 | 2015 | 224 | 0.110 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2015 | 627 | 0.110 |
Why?
| | Guideline Adherence | 1 | 2019 | 585 | 0.110 |
Why?
| | Aging | 1 | 2005 | 1983 | 0.110 |
Why?
| | Palliative Care | 4 | 2010 | 1032 | 0.100 |
Why?
| | History, 20th Century | 1 | 2015 | 330 | 0.100 |
Why?
| | Biopsy | 5 | 2019 | 1073 | 0.100 |
Why?
| | Coloring Agents | 2 | 2015 | 88 | 0.100 |
Why?
| | Wrist Injuries | 1 | 2014 | 23 | 0.100 |
Why?
| | Cumulative Trauma Disorders | 1 | 2014 | 30 | 0.100 |
Why?
| | Premedication | 3 | 1990 | 45 | 0.100 |
Why?
| | Risk Factors | 7 | 2019 | 10840 | 0.100 |
Why?
| | Anti-Bacterial Agents | 3 | 2017 | 1935 | 0.100 |
Why?
| | Information Systems | 1 | 1993 | 58 | 0.100 |
Why?
| | Wrist Joint | 1 | 2014 | 72 | 0.100 |
Why?
| | Prospective Studies | 8 | 2019 | 8087 | 0.100 |
Why?
| | Occupational Injuries | 1 | 2014 | 49 | 0.100 |
Why?
| | Physicians | 2 | 2020 | 954 | 0.100 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 727 | 0.100 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 632 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2020 | 942 | 0.100 |
Why?
| | Epitopes | 2 | 2025 | 479 | 0.090 |
Why?
| | Posture | 2 | 2014 | 180 | 0.090 |
Why?
| | Family | 2 | 2015 | 680 | 0.090 |
Why?
| | Patient Education as Topic | 2 | 2015 | 769 | 0.090 |
Why?
| | Sympathomimetics | 1 | 2012 | 19 | 0.090 |
Why?
| | Societies, Medical | 2 | 1994 | 901 | 0.090 |
Why?
| | Mucositis | 1 | 2012 | 20 | 0.090 |
Why?
| | Caregivers | 2 | 2020 | 1079 | 0.090 |
Why?
| | Disease Progression | 5 | 2019 | 2857 | 0.090 |
Why?
| | Poisson Distribution | 1 | 2012 | 77 | 0.090 |
Why?
| | Pregnenediones | 1 | 2012 | 15 | 0.090 |
Why?
| | Recurrence | 3 | 2004 | 1125 | 0.090 |
Why?
| | Health Surveys | 2 | 2012 | 511 | 0.090 |
Why?
| | Patient Compliance | 2 | 2016 | 587 | 0.090 |
Why?
| | Disease Management | 3 | 2024 | 649 | 0.090 |
Why?
| | Oximetry | 2 | 1990 | 124 | 0.090 |
Why?
| | Cohort Studies | 5 | 2022 | 6045 | 0.080 |
Why?
| | Child Development | 1 | 2016 | 481 | 0.080 |
Why?
| | Self Care | 1 | 2014 | 396 | 0.080 |
Why?
| | Patient Satisfaction | 1 | 2015 | 698 | 0.080 |
Why?
| | Stents | 3 | 2000 | 551 | 0.080 |
Why?
| | Biomarkers | 2 | 2020 | 4329 | 0.080 |
Why?
| | Feeding and Eating Disorders of Childhood | 1 | 2010 | 6 | 0.080 |
Why?
| | Symptom Assessment | 1 | 2012 | 137 | 0.080 |
Why?
| | Bacterial Proteins | 1 | 2017 | 976 | 0.080 |
Why?
| | Metaplasia | 2 | 2022 | 54 | 0.080 |
Why?
| | Curriculum | 1 | 2017 | 1074 | 0.080 |
Why?
| | Immunoassay | 1 | 2010 | 108 | 0.080 |
Why?
| | Health Policy | 1 | 1993 | 399 | 0.080 |
Why?
| | Cathartics | 1 | 1990 | 15 | 0.080 |
Why?
| | Citrates | 1 | 1990 | 41 | 0.080 |
Why?
| | Flavoring Agents | 1 | 1990 | 11 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1370 | 0.080 |
Why?
| | Phenotype | 1 | 2018 | 3186 | 0.080 |
Why?
| | Regression Analysis | 1 | 2012 | 994 | 0.080 |
Why?
| | Immunologic Factors | 2 | 2022 | 244 | 0.080 |
Why?
| | Diet Surveys | 2 | 2024 | 89 | 0.070 |
Why?
| | Duodenoscopy | 1 | 1989 | 8 | 0.070 |
Why?
| | Adaptation, Psychological | 1 | 2015 | 718 | 0.070 |
Why?
| | Gastroscopy | 1 | 1989 | 18 | 0.070 |
Why?
| | Epithelial Cells | 2 | 2014 | 1118 | 0.070 |
Why?
| | Food, Formulated | 1 | 2009 | 16 | 0.070 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2013 | 352 | 0.070 |
Why?
| | Drainage | 1 | 2010 | 187 | 0.070 |
Why?
| | Lasers | 3 | 1985 | 127 | 0.070 |
Why?
| | Maternal Exposure | 1 | 2010 | 189 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1223 | 0.070 |
Why?
| | Physician-Patient Relations | 1 | 1993 | 595 | 0.070 |
Why?
| | Light Coagulation | 1 | 1988 | 10 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2024 | 17291 | 0.070 |
Why?
| | Physical Examination | 1 | 2009 | 236 | 0.060 |
Why?
| | Cholestasis | 1 | 2010 | 215 | 0.060 |
Why?
| | Precancerous Conditions | 2 | 2019 | 162 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 992 | 0.060 |
Why?
| | Digestive System | 2 | 2002 | 29 | 0.060 |
Why?
| | Hypnotics and Sedatives | 1 | 1989 | 221 | 0.060 |
Why?
| | Feces | 1 | 1990 | 494 | 0.060 |
Why?
| | Risk Reduction Behavior | 2 | 2019 | 219 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1511 | 0.060 |
Why?
| | Ovomucin | 1 | 2026 | 7 | 0.060 |
Why?
| | Immunologic Tests | 1 | 2005 | 16 | 0.060 |
Why?
| | Aged | 15 | 2019 | 26251 | 0.060 |
Why?
| | Remission, Spontaneous | 1 | 2005 | 39 | 0.060 |
Why?
| | Comorbidity | 2 | 2025 | 1652 | 0.060 |
Why?
| | Sepsis | 2 | 1989 | 668 | 0.060 |
Why?
| | Equipment Design | 2 | 2005 | 519 | 0.060 |
Why?
| | Equipment Safety | 1 | 2005 | 38 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3396 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 473 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1992 | 0.050 |
Why?
| | Dietetics | 2 | 2017 | 24 | 0.050 |
Why?
| | Esophageal and Gastric Varices | 1 | 1985 | 34 | 0.050 |
Why?
| | Administration, Intranasal | 1 | 2024 | 94 | 0.050 |
Why?
| | Immunoglobulin G | 3 | 2014 | 899 | 0.050 |
Why?
| | Procainamide | 1 | 1984 | 6 | 0.050 |
Why?
| | Hyperplasia | 2 | 2022 | 164 | 0.050 |
Why?
| | Nutrition Assessment | 1 | 2024 | 90 | 0.050 |
Why?
| | Therapeutic Irrigation | 1 | 1984 | 69 | 0.050 |
Why?
| | Pollen | 1 | 2023 | 18 | 0.050 |
Why?
| | Intestinal Absorption | 1 | 1984 | 103 | 0.050 |
Why?
| | Excipients | 1 | 2023 | 55 | 0.050 |
Why?
| | Turkey | 1 | 2022 | 20 | 0.050 |
Why?
| | Digestive System Diseases | 1 | 2002 | 28 | 0.050 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2024 | 178 | 0.050 |
Why?
| | Immunity | 1 | 2023 | 140 | 0.050 |
Why?
| | Vitamins | 1 | 2024 | 183 | 0.050 |
Why?
| | Delphi Technique | 1 | 2024 | 347 | 0.040 |
Why?
| | Metals | 2 | 2000 | 137 | 0.040 |
Why?
| | Software | 1 | 2007 | 673 | 0.040 |
Why?
| | Hemoglobinuria, Paroxysmal | 1 | 2002 | 7 | 0.040 |
Why?
| | Heart Rate | 1 | 2026 | 844 | 0.040 |
Why?
| | HLA Antigens | 1 | 2022 | 241 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4565 | 0.040 |
Why?
| | Respiratory Sounds | 1 | 2021 | 102 | 0.040 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2020 | 28 | 0.040 |
Why?
| | Educational Personnel | 1 | 2020 | 11 | 0.040 |
Why?
| | Terbutaline | 1 | 2020 | 7 | 0.040 |
Why?
| | Injections | 1 | 2021 | 199 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2002 | 217 | 0.040 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2000 | 14 | 0.040 |
Why?
| | Japan | 1 | 2000 | 149 | 0.040 |
Why?
| | Cholestasis, Intrahepatic | 1 | 2000 | 29 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 2021 | 186 | 0.040 |
Why?
| | Albuterol | 1 | 2020 | 76 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2020 | 69 | 0.040 |
Why?
| | China | 1 | 2000 | 278 | 0.040 |
Why?
| | Interprofessional Relations | 2 | 1994 | 274 | 0.040 |
Why?
| | Food Contamination | 1 | 2019 | 36 | 0.040 |
Why?
| | Medical History Taking | 1 | 2019 | 116 | 0.040 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2018 | 77 | 0.040 |
Why?
| | Intestines | 1 | 2002 | 351 | 0.040 |
Why?
| | Esophagogastric Junction | 1 | 2019 | 54 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 585 | 0.030 |
Why?
| | Health Planning Guidelines | 1 | 2018 | 23 | 0.030 |
Why?
| | Ischemia | 1 | 2002 | 421 | 0.030 |
Why?
| | New Zealand | 1 | 2018 | 56 | 0.030 |
Why?
| | Efferent Pathways | 1 | 1998 | 19 | 0.030 |
Why?
| | Psychometrics | 1 | 2022 | 708 | 0.030 |
Why?
| | Food Labeling | 1 | 2017 | 11 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2455 | 0.030 |
Why?
| | Hydrolysis | 1 | 2018 | 195 | 0.030 |
Why?
| | Locus Coeruleus | 1 | 1998 | 25 | 0.030 |
Why?
| | Markov Chains | 1 | 2018 | 128 | 0.030 |
Why?
| | Early Medical Intervention | 1 | 2018 | 59 | 0.030 |
Why?
| | Cross Reactions | 1 | 2017 | 129 | 0.030 |
Why?
| | Immune Sera | 1 | 2017 | 77 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2021 | 377 | 0.030 |
Why?
| | Skin Irritancy Tests | 1 | 2017 | 4 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2019 | 141 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2019 | 538 | 0.030 |
Why?
| | Metiamide | 1 | 1977 | 1 | 0.030 |
Why?
| | Australia | 1 | 2018 | 291 | 0.030 |
Why?
| | Thiourea | 1 | 1977 | 41 | 0.030 |
Why?
| | Agranulocytosis | 1 | 1977 | 30 | 0.030 |
Why?
| | Guanidines | 1 | 1977 | 39 | 0.030 |
Why?
| | RNA, Viral | 1 | 2021 | 691 | 0.030 |
Why?
| | Nutritional Sciences | 1 | 2017 | 35 | 0.030 |
Why?
| | Societies, Scientific | 1 | 2017 | 50 | 0.030 |
Why?
| | Norepinephrine | 1 | 1998 | 201 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2017 | 181 | 0.030 |
Why?
| | Protective Factors | 1 | 2017 | 97 | 0.030 |
Why?
| | Transgenes | 1 | 2017 | 178 | 0.030 |
Why?
| | Uncertainty | 1 | 2017 | 145 | 0.030 |
Why?
| | Probability | 1 | 2017 | 308 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2017 | 200 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2016 | 27 | 0.030 |
Why?
| | Incidence | 2 | 2019 | 2910 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 2016 | 170 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 2239 | 0.030 |
Why?
| | Imidazoles | 1 | 1977 | 244 | 0.030 |
Why?
| | Iodides | 1 | 2015 | 11 | 0.030 |
Why?
| | Radio Waves | 1 | 2015 | 28 | 0.030 |
Why?
| | Mouth | 1 | 2015 | 84 | 0.030 |
Why?
| | Mass Screening | 2 | 2019 | 1300 | 0.030 |
Why?
| | Endoscopes | 2 | 1985 | 17 | 0.030 |
Why?
| | Calpain | 1 | 2014 | 61 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 2007 | 0.030 |
Why?
| | Mice | 1 | 2011 | 18266 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 313 | 0.030 |
Why?
| | Treatment Failure | 1 | 2015 | 358 | 0.030 |
Why?
| | Synapses | 1 | 1998 | 447 | 0.020 |
Why?
| | Organ Specificity | 1 | 2014 | 306 | 0.020 |
Why?
| | Steroids | 1 | 2014 | 160 | 0.020 |
Why?
| | Longitudinal Studies | 2 | 2012 | 3005 | 0.020 |
Why?
| | Population Surveillance | 1 | 2017 | 477 | 0.020 |
Why?
| | Interleukin-13 | 1 | 2014 | 149 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2000 | 699 | 0.020 |
Why?
| | Public Opinion | 1 | 1993 | 61 | 0.020 |
Why?
| | Eosinophil Granule Proteins | 1 | 2012 | 15 | 0.020 |
Why?
| | Lysophospholipase | 1 | 2012 | 10 | 0.020 |
Why?
| | Haplotypes | 1 | 2014 | 505 | 0.020 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2012 | 24 | 0.020 |
Why?
| | Aged, 80 and over | 5 | 2010 | 8351 | 0.020 |
Why?
| | Forecasting | 1 | 1994 | 386 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1156 | 0.020 |
Why?
| | Movement | 1 | 2014 | 290 | 0.020 |
Why?
| | Models, Genetic | 1 | 2014 | 537 | 0.020 |
Why?
| | Biomedical Research | 1 | 2018 | 724 | 0.020 |
Why?
| | Mucous Membrane | 1 | 2012 | 129 | 0.020 |
Why?
| | Survival Rate | 2 | 2010 | 2078 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 840 | 0.020 |
Why?
| | Range of Motion, Articular | 1 | 2014 | 437 | 0.020 |
Why?
| | Abdominal Pain | 2 | 2002 | 148 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 880 | 0.020 |
Why?
| | Specimen Handling | 1 | 2012 | 178 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4082 | 0.020 |
Why?
| | Joint Commission on Accreditation of Healthcare Organizations | 1 | 1990 | 8 | 0.020 |
Why?
| | Professional Role | 1 | 2012 | 171 | 0.020 |
Why?
| | Age of Onset | 1 | 2012 | 557 | 0.020 |
Why?
| | Glycoproteins | 1 | 2012 | 355 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2014 | 868 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2012 | 777 | 0.020 |
Why?
| | Gallbladder Neoplasms | 1 | 2010 | 20 | 0.020 |
Why?
| | Midazolam | 1 | 1990 | 69 | 0.020 |
Why?
| | Citric Acid | 1 | 1990 | 33 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2022 | 2962 | 0.020 |
Why?
| | Endocarditis, Bacterial | 1 | 1989 | 46 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 207 | 0.020 |
Why?
| | Computer Simulation | 1 | 2014 | 1014 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1866 | 0.020 |
Why?
| | Genetic Variation | 1 | 2014 | 992 | 0.020 |
Why?
| | Health Status | 1 | 2014 | 822 | 0.020 |
Why?
| | Cholangiocarcinoma | 1 | 2010 | 110 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 5875 | 0.020 |
Why?
| | Neurons | 1 | 1998 | 1663 | 0.020 |
Why?
| | Bile Duct Neoplasms | 1 | 2010 | 132 | 0.020 |
Why?
| | Pneumoperitoneum | 1 | 1988 | 12 | 0.020 |
Why?
| | Pancreatic Neoplasms | 2 | 2010 | 944 | 0.020 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 1988 | 20 | 0.020 |
Why?
| | Electrocoagulation | 1 | 1987 | 35 | 0.020 |
Why?
| | Social Support | 1 | 2012 | 644 | 0.020 |
Why?
| | Cell Movement | 1 | 2012 | 950 | 0.020 |
Why?
| | Anxiety | 1 | 2015 | 1118 | 0.020 |
Why?
| | Anesthesiology | 1 | 1990 | 178 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2014 | 1526 | 0.020 |
Why?
| | Gastrostomy | 1 | 1988 | 123 | 0.020 |
Why?
| | Electrocardiography | 1 | 1990 | 666 | 0.020 |
Why?
| | Pediatrics | 1 | 2015 | 1122 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2015 | 1169 | 0.010 |
Why?
| | Parents | 1 | 2015 | 1393 | 0.010 |
Why?
| | Duodenal Ulcer | 1 | 1985 | 12 | 0.010 |
Why?
| | Genetic Markers | 1 | 2006 | 337 | 0.010 |
Why?
| | Drug Design | 1 | 2006 | 179 | 0.010 |
Why?
| | Hemostatic Techniques | 1 | 1985 | 50 | 0.010 |
Why?
| | Arteriovenous Malformations | 1 | 1985 | 34 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1985 | 160 | 0.010 |
Why?
| | Random Allocation | 1 | 1985 | 365 | 0.010 |
Why?
| | Electrolytes | 1 | 1984 | 52 | 0.010 |
Why?
| | Stomach Neoplasms | 1 | 1985 | 128 | 0.010 |
Why?
| | Quinidine | 1 | 1983 | 5 | 0.010 |
Why?
| | Health Services Accessibility | 1 | 2012 | 1101 | 0.010 |
Why?
| | Tablets | 1 | 1983 | 41 | 0.010 |
Why?
| | Cholelithiasis | 1 | 2002 | 36 | 0.010 |
Why?
| | Gallstones | 1 | 2002 | 35 | 0.010 |
Why?
| | Streptococcal Infections | 1 | 1985 | 179 | 0.010 |
Why?
| | Biliary Tract Neoplasms | 1 | 2002 | 30 | 0.010 |
Why?
| | Colonic Diseases | 1 | 1982 | 36 | 0.010 |
Why?
| | Iran | 1 | 2002 | 39 | 0.010 |
Why?
| | Jejunum | 1 | 2002 | 36 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 870 | 0.010 |
Why?
| | Pancreatitis | 1 | 2002 | 146 | 0.010 |
Why?
| | Duodenum | 1 | 2002 | 76 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 182 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2002 | 384 | 0.010 |
Why?
| | Age Distribution | 1 | 2002 | 395 | 0.010 |
Why?
| | Rectal Neoplasms | 1 | 1982 | 159 | 0.010 |
Why?
| | Sex Distribution | 1 | 2002 | 379 | 0.010 |
Why?
| | Dogs | 1 | 1982 | 516 | 0.010 |
Why?
| | Granulation Tissue | 1 | 2000 | 6 | 0.010 |
Why?
| | Foreign-Body Reaction | 1 | 2000 | 34 | 0.010 |
Why?
| | Pruritus | 1 | 2000 | 60 | 0.010 |
Why?
| | Equipment Failure Analysis | 1 | 2000 | 124 | 0.010 |
Why?
| | Acute Disease | 1 | 2002 | 1033 | 0.010 |
Why?
| | Aspirin | 1 | 1983 | 404 | 0.010 |
Why?
| | Axonal Transport | 1 | 1998 | 26 | 0.010 |
Why?
| | Neuropeptides | 1 | 1998 | 75 | 0.010 |
Why?
| | Fibrosis | 1 | 2000 | 568 | 0.010 |
Why?
| | Neurons, Afferent | 1 | 1998 | 102 | 0.010 |
Why?
| | Tracheoesophageal Fistula | 1 | 1997 | 38 | 0.010 |
Why?
| | Biocompatible Materials | 1 | 2000 | 429 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2000 | 1486 | 0.010 |
Why?
| | Brain Mapping | 1 | 1998 | 540 | 0.010 |
Why?
| | False Positive Reactions | 1 | 1988 | 124 | 0.000 |
Why?
| | Peptococcus | 1 | 1985 | 1 | 0.000 |
Why?
| | Radiography | 1 | 1988 | 856 | 0.000 |
Why?
| | Drinking | 1 | 1983 | 44 | 0.000 |
Why?
| | Deglutition | 1 | 1983 | 73 | 0.000 |
Why?
| | Esophagitis | 1 | 1983 | 68 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1987 | 1062 | 0.000 |
Why?
| | Pilot Projects | 1 | 1987 | 1878 | 0.000 |
Why?
|
|
Fleischer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|